semaglutide booster Compounded Tablets DietWorks GLP-1 Companion, Semaglutide Support,

This is a significant information gap

In a cohort of 7 patients with DT2 and obesity, daily use of liraglutide 1.2mg achieved, after 10 weeks, a weight reduction of 5% and a decrease in BMI of 2kg/m2.80 In another study, 3 patients with DT2 and obesity achieved a decrease in BMI of between 0.8 and 3.8kg/m2 after 18 weeks with this same dose of liraglutide.81 Another 2 patients with obesity and DT2 achieved weight losses of more than 5kg and a decrease in BMI of 1.5 and 2kg/m2 after 6 weeks of treatment.82 Finally, in a series of 20 subjects with obesity and DT2, an average weight loss of 4.7kg was reported after 8 weeks of treatment with liraglutide 1.8mg.83 In most of these patients, improvements in the psoriasis area severity index (PASI) was observed, and on occasions, a decrease in psoriatic plaques

Long-term study results are currently limited, but the following must be considered for shaping the clinical algorithm in GLP-1 RA prescribing: proper indication, the characteristics of the prescribed drug, the patient's psychiatric and somatic history, sociodemographic factors, patient expectations, and especially monitoring of response to rapid weight loss (Figure 1)

accelerated development of oral obesity and diabetes therapies targeting the GLP-1 pathway

What side effects are common with GLP-1 medication